Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Boston Common Asset Management LLC

Boston Common Asset Management LLC raised its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 3,060.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,711 shares of the medical research company's stock after purchasing an additional 21,024 shares during the period. Boston Common Asset Management LLC's holdings in Amgen were worth $5,659,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Saxon Interests Inc. grew its stake in Amgen by 4.2% during the 4th quarter. Saxon Interests Inc. now owns 2,074 shares of the medical research company's stock worth $541,000 after buying an additional 83 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $15,410,000. Wealthcare Advisory Partners LLC grew its position in Amgen by 3.2% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 13,313 shares of the medical research company's stock worth $3,470,000 after purchasing an additional 416 shares during the last quarter. Procyon Advisors LLC grew its holdings in shares of Amgen by 4.1% during the fourth quarter. Procyon Advisors LLC now owns 9,748 shares of the medical research company's stock worth $2,541,000 after buying an additional 385 shares during the last quarter. Finally, Tompkins Financial Corp grew its stake in shares of Amgen by 50.9% in the 4th quarter. Tompkins Financial Corp now owns 48,892 shares of the medical research company's stock valued at $12,743,000 after purchasing an additional 16,481 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AMGN. William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Piper Sandler Companies reaffirmed an "overweight" rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Bank of America reissued an "underperform" rating and set a $256.00 price target on shares of Amgen in a research note on Tuesday, December 10th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $314.91.

Amgen Stock Up 1.0 %

Shares of NASDAQ:AMGN traded up $2.68 during midday trading on Friday, hitting $272.11. 3,244,015 shares of the company's stock traded hands, compared to its average volume of 3,140,853. The firm's fifty day moving average price is $273.95 and its two-hundred day moving average price is $307.22. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a market cap of $146.27 billion, a PE ratio of 34.84, a P/E/G ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company's revenue was up 23.2% on a year-over-year basis. During the same period last year, the business posted $4.96 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. This is a positive change from Amgen's previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen's payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.